Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Cancer Res. 2011 Feb 1;71(6):2328–2338. doi: 10.1158/0008-5472.CAN-10-2738

Figure 4. Knockdown of DCAMKL-1 inhibits EMT.

Figure 4

(A) DCAMKL-1 specific siRNA (siDCAMKL-1) decreases DCAMKL-1 mRNA expression (left panel), DCAMKL-1 protein expression (middle panel) and increases expression of pri-miR-200a (right panel) compared to scrambled siRNA (siSCR)-treated or Control untreated AsPC-1 human pancreatic cancer cells. (B) AsPC-1-siDCAMKL-1 cancer cells demonstrated decreased expression ZEB1 (left panel), ZEB2 (middle panel) and rescues/upregulates E-cadherin (right panel). (C) DCAMKL-1 (red) and Snail (green) in human pancreatic adenocarcinoma. Co-localization demonstrated in merged image and nuclei are stained blue with Hoechst dye (100X). (D) DCAMKL-1 (red) and Slug (green) in human pancreatic adenocarcinoma. Co-localization demonstrated in merged image and nuclei are stained blue with Hoechst dye (100X). (E) siRNA-mediated knockdown of DCAMKL-1 decreases Snail (left panel), Slug (middle panel) and Twist (right panel) mRNA expression in AsPC-1 cancer cells.

Insets in the images on the right in the panel C and D are magnified images. For panels A, B and E values given as mean ± SEM, and asterisks denote statistically significant differences (*p<0.01) compared with control.